PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33138176-8	2020	Intrarectal treatment of colitis with 30 mg/kg chitosan alone and with 30 mg/kg 5-ASA for 3 days led to a significant decrease in MPO, ALP, TNF-alpha, IL-6, IL-1beta and NF-kappaB in colitis mice compared to untreated mice.	Mesalamine	80-85	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	170-179	
10602313-3	1999	The aim of the present study was to investigate if sulfasalazine and its colonic metabolites 5-aminosalicylic acid (5ASA) and sulfapyridine affect NF-kappaB/Rel activation and viability of T-lymphocytes.	Mesalamine	93-114	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	147-156	
28275298-12	2017	Comparing with the DSS group, the mRNA level of IL-1beta, IL-8, TNF-alpha and NF-kappaB was significantly reduced by 5-ASA and JPQCD.	Mesalamine	117-122	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	78-87	
26642326-8	2015	Further, the up-regulation in mRNA level of colonic TNF-alpha as well as NFkappaB and JAK2 phosphorylation caused by DSS were more pronouncedly reversed in animals treated with the combination therapy than those treated with 5-ASA alone.	Mesalamine	225-230	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	73-81	
10593965-3	1999	We recently reported that 5-aminosalicylic acid (5-ASA) inhibits TNFalpha-regulated IkappaB degradation and NFkappaB activation.	Mesalamine	26-47	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	108-116	
10593965-3	1999	We recently reported that 5-aminosalicylic acid (5-ASA) inhibits TNFalpha-regulated IkappaB degradation and NFkappaB activation.	Mesalamine	49-54	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	108-116	
10593965-11	1999	These findings suggest a novel role for 5-ASA in the management of IBD by disrupting TNFalpha activation of NFkappaB.	Mesalamine	40-45	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	108-116	
10602313-3	1999	The aim of the present study was to investigate if sulfasalazine and its colonic metabolites 5-aminosalicylic acid (5ASA) and sulfapyridine affect NF-kappaB/Rel activation and viability of T-lymphocytes.	Mesalamine	116-120	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	147-156	
10029619-0	1999	Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes.	Mesalamine	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	77-83	
10029619-9	1999	TNF-alpha-stimulated NF-kappaB activation and nuclear translocation and the degradation of Ikappa-Balpha were blocked by mesalamine.	Mesalamine	121-131	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	21-30	
10029619-10	1999	CONCLUSIONS: Mesalamine inhibits TNF-alpha-mediated effects on intestinal epithelial cell proliferation and activation of MAP kinase and NF-kappaB.	Mesalamine	13-23	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	137-146	
35303008-5	2022	Furthermore, results suggested that the nuclear factor-kappa B (NF-kappaB) pathway may be involved in the promotion of SAA1 expression by flagellin, which was inhibited by treatment with 5-aminosalicylic acid (5-ASA).	Mesalamine	187-208	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	40-62	
35303008-5	2022	Furthermore, results suggested that the nuclear factor-kappa B (NF-kappaB) pathway may be involved in the promotion of SAA1 expression by flagellin, which was inhibited by treatment with 5-aminosalicylic acid (5-ASA).	Mesalamine	187-208	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	64-73	
35303008-5	2022	Furthermore, results suggested that the nuclear factor-kappa B (NF-kappaB) pathway may be involved in the promotion of SAA1 expression by flagellin, which was inhibited by treatment with 5-aminosalicylic acid (5-ASA).	Mesalamine	210-215	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	40-62	
35303008-5	2022	Furthermore, results suggested that the nuclear factor-kappa B (NF-kappaB) pathway may be involved in the promotion of SAA1 expression by flagellin, which was inhibited by treatment with 5-aminosalicylic acid (5-ASA).	Mesalamine	210-215	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	64-73	
35303008-6	2022	Therefore, the flagellin/NF-kappaB/SAA1 axis may represent one of the mechanisms by which 5-ASA suppresses intestinal inflammation.	Mesalamine	90-95	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	25-34